Tiagabine is a novel antiepileptic drug which acts by decreasing gamma aminobutyric acid uptake in astrocytes and neurones. Here the first case of deliberate overdose with this compound in a patient on concomitant phenytoin is reported. On admission to hospital his conscious level deteriorated to grade III coma. No changes in the electrocardiogram were noted. Recovery from the initial effects was rapid, and there were no sequelae. Plasma levels of tiagabine (3.1 p,g/ml) 4 hours after ingestion were 30 times higher than at typical steady state during therapeutic dosing. The effects of poisoning with current first-line antiepileptic drugs are reviewed. The newer agents, particularly those with greater biochemical specificity, may be safer in overdose than the more established anticonvulsants.
INTRODUCTION CASE REPORT
Epileptic patients are at greater risk of self poisoning than other patient groups ~. Safety in overdose should, therefore, be an important consideration when choosing an antiepileptic drug. Tiagabine is a novel anticonvulsant, which is currently undergoing phase III trials worldwide 2. It is a nipecotic acid derivative with a lipophilic anchor, which allows it to cross the blood-brain barrier. Tiagabine acts by blocking the re-uptake of the inhibitory neurotransmitter gamma animobutyric acid (GABA) into glial cells and neurones ~. The resultant increase in synaptic GABA concentration is thought to be responsible for its anticonvulsant action 4. After oral administration, it is rapidly absorbed and metabolized in the liver with a half-life of between 4 and 13 hours. Although sedation has been reported, preliminary data suggest that tiagabine does not impair cognition at therapeutic dosage 5. We report the first case of deliberate overdose with tiagabine.
DR is a 30-year-old man who has suffered from complex partial and secondary generalized seizures of unknown aetiology since the age of three. Surface electroencephalography demonstrated recurrent focal epileptiform discharge in the right fronto-temporal area. Computerized tomography of the brain was normal. Prior to this episode he had been taking tiagabine (64mg daily) in addition to his usual dose of phenytoin (200 mg daily) with substantial benefit under an open protocol for the previous 9 months. Following an argument with his girlfriend, the patient took 320mg of tiagabine together with 400mg phenytoin. One hour later, he became drowsy and he was admitted to the local hospital. His conscious level deteriorated rapidly, reaching grade III coma overnight. Routine biochemistry, liver function tests and full blood counts were all normal. No active intervention was undertaken and the patient recovered fully. No neurological deficit could be demonstrated 12 hours after admission. Serial electrocardiograms showed no abnormality through his hospital stay. Tiagabine and phenytoin plasms concentrations 4 hours after ingestion were 3.1/zg/ml and 22/.tg/ml, respectively. Psychiatric review confirmed that this was an impulsive overdose with no suicidal intent. He was discharged home after 48 hours' observation.
DISCUSSION
The current first-line antiepileptic drugs are all potentially fatal in overdose j, perhaps a consequence of their multiple, non-selective mechanisms of action 6. In a three-year prospective survey of overdoses of non-barbiturate anticonvulsants reported to the UK National Poisons Service, carbamazepine (48%), phenytoin (33%) and sodium valproate were the most frequently ingested 7, perhaps not surprisingly as they are regarded as the antiepileptic drugs of first choice 8.
The initial features of carbamazepine poisoning are those of cerebellar dysfunction. As the concentration increases, central nervous system depression becomes dominant, progressing to respiratory depression in severe cases '. Anticholinergic features appear, presumably as a consequence of carbamazepine's structural similarity to the tricyclic antidepressants. An increase in the frequency of convulsions has been noted, perhaps related to the production of hyponatraemia "~. The risk of cardiac arrhythmias necessitates ECG monitoring for at least 24 hours ~j.
The saturation pharmacokinetics of phenytoin means that the ingestion of even a small dose can produce a substantial increase in circulating concentration ]2. The slow rate of hepatic metabolism can make the recovery period as long as a week j3. The initial features of acute phenytoin toxicity are cerebellar dysfunction including nystagmus, incoordination, dysarthria and ataxia ~4. Depression of the central nervous system (CNS) is common, often progressing to coma. This may be accompanied by hypotension and respiratory depression.
With sodium valproate, central nervous system depression is predominant, although often benign ~5. Coma, however, can occur after ingestion of more than 20mg/kg body weight. Seizures ~6, respiratory failure, bone marrow suppression ~7 and metabolic adverse effects such as acidosis and hypocalcaemia can all occur TM.
Fatalities, although uncommon, have been reported~7"~.
Our patient was receiving treatment with phenytoin and tiagabine prior to the event. The tiagabine concentration four hours after ingestion was 30 times higher than at typical steady state following therapeutic dosage (Dr LC Lassen, pers. comm.). This is equivalent to around 300/xmol/litre of carbamazepine or 450/zmol/ litre of phenytoin. At that time the patient was in light coma. The phenytoin concentration just exceeded the target range, and so was unlikely to contribute to the clinical picture. Induction of tiagabine's metabolism by phenytoin might have contributed to the patient's rapid recovery ~'.
There are no published cases of self poisoning with the GABA transaminase inhibitor vigabatrin, but current information suggests that the only adverse effect is transient drowsiness (Dr J Mumford, pers. comm.). There has been one report of lamotrigine overdose, in which neurological toxicity was a feature:". This is the first report of tiagabine taken in overdose in man, and the rapid, uneventful recovery is, we believe, reassuring for this vulnerable patient population. One of the individual benefits of the newer antiepileptic drugs may be that their increased biochemical specificity augments existing physiological processes, even in overdose, rather than producing a 'blunderbuss' deleterious effect on a range of cerebral functions and peripheral tissues. Consequently, anticonvulsants with defined mechanisms of action may be safer in overdose than the more established agents.
